These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 23074158)

  • 1. Monocytes and γδ T cells control the acute-phase response to intravenous zoledronate: insights from a phase IV safety trial.
    Welton JL; Morgan MP; Martí S; Stone MD; Moser B; Sewell AK; Turton J; Eberl M
    J Bone Miner Res; 2013 Mar; 28(3):464-71. PubMed ID: 23074158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluvastatin does not prevent the acute-phase response to intravenous zoledronic acid in post-menopausal women.
    Thompson K; Keech F; McLernon DJ; Vinod K; May RJ; Simpson WG; Rogers MJ; Reid DM
    Bone; 2011 Jul; 49(1):140-5. PubMed ID: 21047568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zoledronate promotes inflammatory cytokine expression in human CD14-positive monocytes among peripheral mononuclear cells in the presence of γδ T cells.
    Takimoto R; Suzawa T; Yamada A; Sasa K; Miyamoto Y; Yoshimura K; Sasama Y; Tanaka M; Kinoshita M; Ikezaki K; Ichikawa M; Yamamoto M; Shirota T; Kamijo R
    Immunology; 2021 Mar; 162(3):306-313. PubMed ID: 33131052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gamma-delta T lymphocytes and 25-hydroxy vitamin D levels as key factors in autoimmunity and inflammation: the case of zoledronic acid-induced acute phase reaction.
    De Santis M; Cavaciocchi F; Ceribelli A; Crotti C; Generali E; Fabbriciani G; Selmi C; Massarotti M
    Lupus; 2015 Apr; 24(4-5):442-7. PubMed ID: 25801887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors.
    Noguchi A; Kaneko T; Kamigaki T; Fujimoto K; Ozawa M; Saito M; Ariyoshi N; Goto S
    Cytotherapy; 2011 Jan; 13(1):92-7. PubMed ID: 20831354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.
    Dieli F; Vermijlen D; Fulfaro F; Caccamo N; Meraviglia S; Cicero G; Roberts A; Buccheri S; D'Asaro M; Gebbia N; Salerno A; Eberl M; Hayday AC
    Cancer Res; 2007 Aug; 67(15):7450-7. PubMed ID: 17671215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expansion of human peripheral blood γδ T cells using zoledronate.
    Kondo M; Izumi T; Fujieda N; Kondo A; Morishita T; Matsushita H; Kakimi K
    J Vis Exp; 2011 Sep; (55):. PubMed ID: 21931292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma.
    Lang JM; Kaikobad MR; Wallace M; Staab MJ; Horvath DL; Wilding G; Liu G; Eickhoff JC; McNeel DG; Malkovsky M
    Cancer Immunol Immunother; 2011 Oct; 60(10):1447-60. PubMed ID: 21647691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zoledronate rescues immunosuppressed monocytes in sepsis patients.
    Raffray L; Burton RJ; Baker SE; Morgan MP; Eberl M
    Immunology; 2020 Jan; 159(1):88-95. PubMed ID: 31606902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gamma delta T cells from HIV+ donors can be expanded in vitro by zoledronate/interleukin-2 to become cytotoxic effectors for antibody-dependent cellular cytotoxicity.
    Poonia B; Pauza CD
    Cytotherapy; 2012 Feb; 14(2):173-81. PubMed ID: 22029653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid.
    Fiore F; Castella B; Nuschak B; Bertieri R; Mariani S; Bruno B; Pantaleoni F; Foglietta M; Boccadoro M; Massaia M
    Blood; 2007 Aug; 110(3):921-7. PubMed ID: 17403919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating γδ T cells and the risk of acute-phase response after zoledronic acid administration.
    Rossini M; Adami S; Viapiana O; Ortolani R; Vella A; Fracassi E; Gatti D
    J Bone Miner Res; 2012 Jan; 27(1):227-30. PubMed ID: 21956654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with acute-phase response of bisphosphonate-naïve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate.
    Popp AW; Senn R; Curkovic I; Senn C; Buffat H; Popp PF; Lippuner K
    Osteoporos Int; 2017 Jun; 28(6):1995-2002. PubMed ID: 28299378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DC-like cell-dependent activation of human natural killer cells by the bisphosphonate zoledronic acid is regulated by γδ T lymphocytes.
    Nussbaumer O; Gruenbacher G; Gander H; Thurnher M
    Blood; 2011 Sep; 118(10):2743-51. PubMed ID: 21673342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute-phase reaction induced by zoledronate and its effect on prognosis of patients with advanced non-small cell lung cancer.
    Izumi H; Yamasaki A; Takeda K; Kodani M; Touge H; Tanaka N; Yanai M; Ueda Y; Sakamoto T; Nishii-Ito S; Makino H; Yamaguchi K; Igishi T; Shimizu E
    Lung Cancer; 2018 Aug; 122():200-205. PubMed ID: 30032832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zoledronate decreases CTLA-4 in vivo and in vitro independently of its action on bone resorption.
    Giusti A; Camellino D; Saverino D; Iervasi E; Girasole G; Bianchi G; Papapoulos SE
    Bone; 2020 Sep; 138():115512. PubMed ID: 32603908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
    Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
    Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Essential requirements of zoledronate-induced cytokine and γδ T cell proliferative responses.
    Nussbaumer O; Gruenbacher G; Gander H; Komuczki J; Rahm A; Thurnher M
    J Immunol; 2013 Aug; 191(3):1346-55. PubMed ID: 23794630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of cytokines and adipocytokines in zoledronate-induced acute phase reaction in postmenopausal women with low bone mass.
    Anastasilakis AD; Polyzos SA; Delaroudis S; Bisbinas I; Sakellariou GT; Gkiomisi A; Papadopoulou E; Gerou S; Makras P
    Clin Endocrinol (Oxf); 2012 Dec; 77(6):816-22. PubMed ID: 22676573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lysis of aminobisphosphonate-sensitized MCF-7 breast tumor cells by Vγ9Vδ2 T cells.
    Dhar S; Chiplunkar SV
    Cancer Immun; 2010 Nov; 10():10. PubMed ID: 21069948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.